Human Organoids Share Structural and Genetic Features with Primary Pancreatic Adenocarcinoma Tumors
Open accessPublished version of a preprint
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Patient-derived pancreatic ductal adenocarcinoma (PDAC) organoid systems show great promise for understanding the biological underpinnings of disease and advancing therapeutic precision medicine. Despite the increased use of organoids, the fidelity of molecular features, genetic heterogeneity, and drug response to the tumor of origin remain important unanswered questions limiting their utility. To address this gap in knowledge, primary tumor- and patient-derived xenograft (PDX)-derived organoids, and 2D cultures for in-depth genomic and histopathologic comparisons with the primary tumor were created. Histopathologic features and PDAC representative protein markers (e.g., claudin 4 and CA19-9) showed strong concordance. DNA- and RNA-sequencing (RNAseq) of single organoids revealed patient-specific genomic and transcriptomic consistency. Single-cell RNAseq demonstrated that organoids are primarily a clonal population. In drug response assays, organoids displayed patient-specific sensitivities. In addition, the in vivo PDX response to FOLFIRINOX and gemcitabine/abraxane treatments were examined, which was recapitulated in vitro with organoids. This study has demonstrated that organoids are potentially invaluable for precision medicine as well as preclinical drug treatment studies because they maintain distinct patient phenotypes and respond differently to drug combinations and dosage. Implications: The patient-specific molecular and histopathologic fidelity of organoids indicate that they can be used to understand the etiology of the patient's tumor and the differential response to therapies and suggests utility for predicting drug responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
Analysis of protein-coding genetic variation in 60,706 humans
Exome Aggregation Consortium, Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., O’Donnell-Luria, A. H., Ware, J. S., Hill, A. J., et al. (2016) · Nature · doi:10.1038/nature19057 · Cited by 9,587
Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets.
Macosko, E. Z., Basu, A., Satija, R., Nemesh, J., Shekhar, K., Goldman, M., Tirosh, I., Bialas, A. R., Kamitaki, N., Martersteck, E. M., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.002 · Cited by 7,110
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
The third dimension bridges the gap between cell culture and live tissue
Pampaloni, F., Reynaud, E. G., & Stelzer, E. H. K. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2236 · Cited by 2,817 · cited 1×
“PDX models have complex architecture and utilize heterogeneous patient tissue, but the clinical applicability is challenging due to prohibitive time requirements (up to 6 months to establish tumor growth), costs associated with in vivo systems, the large sample size required ( 100 mm(3)), and the influence of infiltra…”
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
Ryan, D. P., Hong, T. S., & Bardeesy, N. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1404198 · Cited by 2,348
Organoid models of human and mouse ductal pancreatic cancer
Boj, S. F., Hwang, C.-I., Baker, L. A., Chio, I. I. C., Engle, D. D., Corbo, V., Jager, M., Ponz-Sarvise, M., Tiriac, H., Spector, M. S., et al. (2015) · Cell · doi:10.1016/j.cell.2014.12.021 · Cited by 2,150
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
Initiative, A. P. C. G., Biankin, A. V., Waddell, N., Kassahn, K. S., Gingras, M.-C., Muthuswamy, L. B., Johns, A. L., Miller, D. K., Wilson, P. J., Patch, A.-M., et al. (2012) · Nature · doi:10.1038/nature11547 · Cited by 2,058
Research works printed but not linked: 37
- Lee, 2006, Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines, Cancer Cell, 9, 391, 10.1016/j.ccr.2006.03.030 · DOI · Paper page
- van Staveren, 2009, Human cancer cell lines: experimental models for cancer cells in situ? For cancer stem cells?, Biochim Biophys Acta, 1795, 92
- Bardeesy, 2006, Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse, Proc Natl Acad Sci U S A, 103, 5947, 10.1073/pnas.0601273103 · DOI · Paper page
- Rubio-Viqueira, 2006, An in vivo platform for translational drug development in pancreatic cancer, Clin Cancer Res, 12, 4652, 10.1158/1078-0432.CCR-06-0113 · DOI · Paper page
- Willey, 2015, Patient-derived xenografts as a model system for radiation research, Semin Radiat Oncol, 25, 273, 10.1016/j.semradonc.2015.05.008 · DOI
- Drost, 2016, Organoid culture systems for prostate epithelial and cancer tissue, Nat Protoc, 11, 347, 10.1038/nprot.2016.006 · DOI · Paper page
- Jarde, 2016, Wnt and Neuregulin1/ErbB signalling extends 3D culture of hormone responsive mammary organoids, Nat Commun, 7, 13207, 10.1038/ncomms13207 · DOI · Paper page
- Moreira, 2018, Pancreas 3D organoids: current and future aspects as a research platform for personalized medicine in pancreatic cancer, Cell Mol Gastroenterol Hepatol, 5, 289, 10.1016/j.jcmgh.2017.12.004 · DOI
- Kleinman, 2003, Role of the extracellular matrix in morphogenesis, Curr Opin Biotechnol, 14, 526, 10.1016/j.copbio.2003.08.002 · DOI · Paper page
- Griffith, 2006, Capturing complex 3D tissue physiology in vitro, Nat Rev Mol Cell Biol, 7, 211, 10.1038/nrm1858 · DOI · Paper page
- Kadri, 2017, Clinical validation of a next-generation sequencing genomic oncology panel via cross-platform benchmarking against established amplicon sequencing assays, J Mol Diagn, 19, 43, 10.1016/j.jmoldx.2016.07.012 · DOI
- Martin, 2011, Cutadapt removes adapter sequences from high-throughput sequencing reads, 10
- Quinlan, 2010, BEDTools: a flexible suite of utilities for comparing genomic features, Bioinformatics, 26, 841, 10.1093/bioinformatics/btq033 · DOI · Paper page
- Cibulskis, 2013, Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples, Nat Biotechnol, 31, 213, 10.1038/nbt.2514 · DOI · Paper page
- Fang, 2016, Indel variant analysis of short-read sequencing data with Scalpel, Nat Protoc, 11, 2529, 10.1038/nprot.2016.150 · DOI
- McLaren, 2010, Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor, Bioinformatics, 26, 2069, 10.1093/bioinformatics/btq330 · DOI · Paper page
- Morgulis, 2006, A fast and symmetric DUST implementation to mask low-complexity DNA sequences, J Comput Biol, 13, 1028, 10.1089/cmb.2006.13.1028 · DOI · Paper page
- Dobin, 2013, STAR: ultrafast universal RNA-seq aligner, Bioinformatics, 29, 15, 10.1093/bioinformatics/bts635 · DOI · Paper page
- Teh, 2006, Hierarchical Dirichlet processes, 1566
- Matros, 2006, Cytokeratin 20 expression identifies a subtype of pancreatic adenocarcinoma with decreased overall survival, Cancer, 106, 693, 10.1002/cncr.21609 · DOI
- Chu, 2000, Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases, Mod Pathol, 13, 962, 10.1038/modpathol.3880175 · DOI · Paper page
- Yemelyanova, 2011, Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis, Mod Pathol, 24, 1248, 10.1038/modpathol.2011.85 · DOI · Paper page
- Boogerd, 2017, Correlation between preoperative serum carcinoembryonic antigen levels and expression on pancreatic and rectal cancer tissue, Biomarkers Cancer, 9, 1179299x17710016, 10.1177/1179299X17710016 · doi:10.1177/1179299x17710016
- Zapata, 2007, Immunohistochemical expression of SMAD4, CK19, and CA19-9 in fine needle aspiration samples of pancreatic adenocarcinoma: utility and potential role, CytoJournal, 4, 13, 10.1186/1742-6413-4-13 · DOI
- Schmuck, 2016, Distal bile duct carcinomas and pancreatic ductal adenocarcinomas: postulating a common tumor entity, Cancer Med, 5, 88, 10.1002/cam4.566 · DOI
- Gnoni, 2013, Carcinogenesis of pancreatic adenocarcinoma: precursor lesions, Int J Mol Sci, 14, 19731, 10.3390/ijms141019731 · DOI
- Ando, 2015, Discrimination of p53 immunohistochemistry-positive tumors by its staining pattern in gastric cancer, Cancer Med, 4, 75, 10.1002/cam4.346 · DOI
- Neesse, 2013, Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions, Gut, 62, 1034, 10.1136/gutjnl-2012-302577 · DOI · Paper page
- Michl, 2001, Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin, Gastroenterology, 121, 678, 10.1053/gast.2001.27124 · DOI · Paper page
- Partyka, 2012, Diverse monoclonal antibodies against the CA 19-9 antigen show variation in binding specificity with consequences for clinical interpretation, Proteomics, 12, 2212, 10.1002/pmic.201100676 · DOI · Paper page
- Ichihara, 1988, Immunohistochemical localization of CA 19-9 and CEA in pancreatic carcinoma and associated diseases, Cancer, 61, 324, 10.1002/1097-0142(19880115)61:2<324::AID-CNCR2820610223>3.0.CO;2-Q · doi:10.1002/1097-0142(19880115)61:2<324::aid-cncr2820610223>3.0.co;2-q
- Allum, 1986, Demonstration of carcinoembryonic antigen (CEA) expression in normal, chronically inflamed, and malignant pancreatic tissue by immunohistochemistry, J Clin Pathol, 39, 610, 10.1136/jcp.39.6.610 · doi:10.1136/jcp.39.6.610
- Jones, 2008, Core signaling pathways in human pancreatic cancers revealed by global genomic analyses, Science, 321, 1801, 10.1126/science.1164368 · DOI · Paper page
- Hori, 2013, Prominin-1 (CD133) reveals new faces of pancreatic progenitor cells and cancer stem cells: current knowledge and therapeutic perspectives, Adv Exp Med Biol, 777, 185, 10.1007/978-1-4614-5894-4_12 · DOI
- Busser, 2011, The multiple roles of amphiregulin in human cancer, Biochim Biophys Acta, 1816, 119
- Wang, 2016, Expression of amphiregulin predicts poor outcome in patients with pancreatic ductal adenocarcinoma, Diagn Pathol, 11, 60, 10.1186/s13000-016-0512-4 · DOI
- Funatomi, 1997, Amphiregulin antisense oligonucleotide inhibits the growth of T3M4 human pancreatic cancer cells and sensitizes the cells to EGF receptor-targeted therapy, Int J Cancer, 72, 512, 10.1002/(SICI)1097-0215(19970729)72:3<512::AID-IJC21>3.0.CO;2-C · doi:10.1002/(sici)1097-0215(19970729)72:3<512::aid-ijc21>3.0.co;2-c
Cited by
Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids
Schuster, B., Junkin, M., Kashaf, S. S., Romero-Calvo, I., Kirby, K., Matthews, J., Weber, C. R., Rzhetsky, A., White, K. P., & Tay, S. (2020) · Nature Communications · doi:10.1038/s41467-020-19058-4 · Cited by 424
Self-citationOrgan-on-a-Chip for Cancer and Immune Organs Modeling
Sun, W., Luo, Z., Lee, J., Kim, H., Lee, K., Tebon, P., Feng, Y., Dokmeci, M. R., Sengupta, S., & Khademhosseini, A. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201801363 · Cited by 221
A pan-cancer organoid platform for precision medicine
Larsen, B. M., Kannan, M., Langer, L. F., Leibowitz, B. D., Bentaieb, A., Cancino, A., Dolgalev, I., Drummond, B. E., Dry, J. R., Ho, C.-S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109429 · Cited by 105
Self-citationPre-clinical Models of Metastasis in Pancreatic Cancer
Miquel, M., Zhang, S., & Pilarsky, C. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.748631 · Cited by 53
Shinkawa, T., Ohuchida, K., Mochida, Y., Sakihama, K., Iwamoto, C., Abe, T., Ideno, N., Mizuuchi, Y., Shindo, K., Ikenaga, N., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02301-9 · Cited by 41
Metadata
- Authors
- Romero-Calvo, I., Weber, C. R., Ray, M., Brown, M., Kirby, K., Nandi, R. K., Long, T. M., Sparrow, S. M., Ugolkov, A., Qiang, W., Zhang, Y., Brunetti, T., Kindler, H., Segal, J. P., Rzhetsky, A., Mazar, A. P., Buschmann, M. M., Weichselbaum, R., Roggin, K., & White, K. P.
- Venue
- Molecular Cancer Research
- Published
- 2019-01-01
- Volume
- 17
- Issue
- 1
- Pages
- 70-83
- ISSN
- 1541-7786 (ISSN-L)
- 1557-3125
- OpenAlex
- W2889176487
- Cited by
- 119
- References
- 18
- FWCI
- 3.71
- Type
- journal article
- Language
- en
- Open access
- green
- Funders
- NIH (U10CA180836)
- NCI (U54CA193419)
- CCSG (P30 CA060553)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Human Organoids Share Structural and Genetic Features with Primary Pancreatic Adenocarcinoma Tumors. https://app.cochat.ai/papers/10.1158/1541-7786.mcr-18-0531
- The paper
- Romero-Calvo, I., Weber, C. R., Ray, M., Brown, M., Kirby, K., Nandi, R. K., Long, T. M., Sparrow, S. M., Ugolkov, A., Qiang, W., Zhang, Y., Brunetti, T., Kindler, H., Segal, J. P., Rzhetsky, A., Mazar, A. P., Buschmann, M. M., Weichselbaum, R., Roggin, K., & White, K. P. (2019). Human Organoids Share Structural and Genetic Features with Primary Pancreatic Adenocarcinoma Tumors. Molecular Cancer Research. https://doi.org/10.1158/1541-7786.mcr-18-0531
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.